- Sulfonyl Ureas
- Di Peptidyl Peptidase (DPP)-IV Inhibitors
- ?-glucosidase Inhibitos
- GLP-1 Agonists
North America Anti diabetic Biosimilars Market size was valued at USD x billion in 2021 and is expected to reach USD x billion by 2028, at a CAGR of x% during the forecast period 2022-2028. Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.
Fastest Growing Market
Drivers: Increase in the prevalence of diabetic patients. Patent expiries block buster drugs and promising product pipeline. Rise in R&D activities for the innovation of Insulin biosimilars Restraints: High cost of R&D activities. Stringent regulatory policies. Complexity in development of biosimilars
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.